To further analyze the difference in pneumonitis incidence and severity between the two groups (ASA-users treated with PD-1 vs. PD-L1 inhibitors), pneumonitis grades were determined according to the National Cancer Institute CTCAE v5.0 Criteria (Table 11). This evidence concerns the gene CD274 and pneumonitis.